Skip to content
Search

Latest Stories

Green Party unveils ambitious NHS investment plan ahead of General Election

Green Party unveils ambitious NHS investment plan ahead of General Election
The Green Party envisions this investment as a means to ensure dignity for those in need and alleviate the burden on NHS services

The Green Party has previewed its upcoming manifesto with a bold proposal for the National Health Service (NHS) and social care system, promising an unprecedented level of investment to restore and enhance these critical services.

By 2030, the Greens aim to inject over £50 billion annually into health and social care, accompanied by an additional £20 billion capital investment to modernise healthcare infrastructure.


Green Party Co-Leader Adrian Ramsay emphasised the urgency of these reforms, stating, "Our NHS is at breaking point following 14 years of underfunding."

"Patients are stuck in hospital corridors, people can’t see their GP or NHS dentist when they need to, and staff are severely overstretched."

The manifesto highlights a comprehensive approach to revitalising the NHS, including:

A £30 billion annual increase for the NHS: This funding aims to raise salaries for frontline workers, ensuring rapid access to GPs and same-day service in urgent cases.

It also pledges universal access to NHS dental care.

Ramsay elaborated, "Greens believe passionately in the NHS and we are the only party to be honest with the public that it’s going to cost money to nurse the NHS back to health after 14 years of Conservative damage."

A £20 billion per year boost for social care: This proposal seeks to address the pressures on the NHS caused by an underfunded care system.

The Green Party envisions this investment as a means to ensure dignity for those in need and alleviate the burden on NHS services.

A £20 billion capital investment: The Greens plan to modernise aging hospitals and primary care facilities, as well as update outdated equipment, bringing them up to contemporary standards.

Co-Leader Carla Denyer underscored the Green Party's commitment to maintaining the public nature of the NHS, saying, "It is only the Greens who are offering a cast-iron guarantee to push back against the creeping privatisation of the NHS."

She contrasted this with other parties, noting, "Wes Streeting, the Shadow Health Secretary, said he would ‘hold the door wide open’ to an increased role for the private sector in our precious NHS."

Pallavi Devulapalli, the Green Party’s Health, Social Care and Public Health spokesperson and a practicing GP, shared her perspective on the impact of underinvestment:

"It breaks my heart when patients come into my surgery and I know they won’t get the care they need in a timely manner. But it doesn’t have to be like this."

"With the political will, we can have an NHS that puts the patient first and ensures world-beating quality of care," she added.

The Greens argue that their plans are not only necessary but also feasible, advocating for a fairer tax system to fund these substantial investments.

Ramsay concluded, "With more Greens in the next Parliament, we will press the new government to take the action needed to restore our NHS."

More For You

Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less
Omega Pharmacy in Derbyshire Finds New Owner in Just 18 Days

Omega Pharmacy

Christie & Co

Omega Pharmacy in Derbyshire sold in just 18 days

Omega Pharmacy in Derbyshire has found a new owner in less than three weeks after being put on the market.

The pharmacy was previously owned by husband-and-wife duo Manny and Poonam Rai, who decided to sell it after a short period of ownership to focus on their other pharmacy in Coventry, according to Christie & Co.

Keep ReadingShow less
DHSC announces second list of March 2025 price concessions

A price concession only applies for the month it is granted.

Getty Images

March price concessions list released; prescription charge remains unchanged

The Department of Health and Social Care (DHSC) has released a second list of price concessions for March 2025, following ongoing discussions with Community Pharmacy England (CPE) regarding medicine pricing concerns raised by pharmacy owners.

A price concession is introduced when pharmacy contractors are unable to source a drug at or below the reimbursement price set out in the Drug Tariff.

Keep ReadingShow less